SCHEMBL307239

SCHEMBL307239

CC(O)=S.CCCC(O)=S

nearest known ligand 0.40

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 3/20 0.40
HDAC3 O15379 3/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC2 Q92769 3/20 0.40
HDAC8 Q9BY41 3/20 0.40
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
TSHR P16473 1/20 0.32
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL37528 0.93
SCHEMBL11506222 0.93 HDAC3 (0.44) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL25238705 0.93 HDAC3 (0.44) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL4293235 0.90
Hydrochloric Acid SCHEMBL9687182 0.90
Hydrochloric Acid SCHEMBL3244716 0.90
SCHEMBL21462107 0.90
SCHEMBL29071751 0.87
SCHEMBL28614154 0.84 FFAR3 (0.38) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL1412288 0.77 FFAR3 (0.33) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2051861-B1 POROUS MEMBRANE AND ITS METHOD OF MANUFACTURE FUJIFILM MFG EUROPE BV (NL) 2011-03-23 EP claimed
EP-4680614-A1 IMPROVED DIRECT SYNTHESIS OF ALKENYLHALOSILANES Momentive Performance Materials Inc. (US) 2026-01-21 EP disclosed
WO-2024191735-A1 IMPROVED DIRECT SYNTHESIS OF ALKENYLHALOSILANES MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2024-09-19 WO disclosed
US-20240309024-A1 DIRECT SYNTHESIS OF ALKENYLHALOSILANES MOMENTIVE PERFORMANCE MAT INC (US) 2024-09-19 US disclosed
EP-2265359-B1 PROCESS FOR PREPARING MEMBRANES FUJIFILM MFG EUROPE BV (NL) 2017-11-22 EP disclosed
US-9290791-B2 Reagents and methods for sirtuin capture CORNELL UNIVERSITY (US) 2016-03-22 US disclosed
US-8419838-B2 Process for preparing membranes FUJIFILM MANUFACTURING EUROPE B.V. (NL) 2013-04-16 US disclosed
US-20130065248-A1 REAGENTS AND METHODS FOR SIRTUIN CAPTURE CORNELL UNIVERSITY (US) 2013-03-14 US disclosed
US-8303691-B2 Composite membranes FUJIFILM MANUFACTURING EUROPE B.V. (NL) 2012-11-06 US disclosed
US-8231710-B2 Membranes and processes for their manufacture and use FUJIFILM MANUFACTURING EUROPE B.V. (NL) 2012-07-31 US disclosed
US-6362189-B1 GRAMNEGATIVE, GRAMPOSITIVE BACTERIA PHARMACIA AND UPJOHN COMPANY 2002-03-26 US disclosed
US-20020016323-A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality PHARMACIA & UPJOHN COMPANY 2002-02-07 US disclosed
US-6342513-B1 THIOCARBONYLAMIDES ON OXAZO-, ISOOXAZOLE OR FURANONE RINGS FOR USE AS BACTERICIDES PHARMACIA AND UPJOHN COMPANY 2002-01-29 US disclosed
US-20010041728-A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality HESTER JACKSON B (US) 2001-11-15 US disclosed
EP-1133493-A1 OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY PHARMACIA & UPJOHN COMPANY (US) 2001-09-19 EP disclosed
US-6255304-B1 AIDS THERAPY PHARMACIA & UPJOHN COMPANY 2001-07-03 US disclosed
WO-2000032599-A1 OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY PHARMACIA & UPJOHN COMPANY (US) 2000-06-08 WO disclosed
EP-0994874-A1 THIADIAZOLYL AND OXADIAZOLYL PHENYL OXAZOLIDINONE ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-04-26 EP disclosed
US-5977373-A Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents PHARMACIA & UPJOHN COMPANY (US) 1999-11-02 US disclosed
WO-1999002525-A1 THIADIAZOLYL AND OXADIAZOLYL PHENYL OXAZOLIDINONE ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240309024-A1 DIRECT SYNTHESIS OF ALKENYLHALOSILANES HRH2, HRH1, HRH3 FFAR3 593/4885HDAC3 1439/4885HDAC1 309/4885
US-20010041728-A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality OXA1L, MRPL21, TOP1 FFAR3 3551/4885HDAC3 996/4885HDAC1 56/4885
US-20020016323-A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality OXA1L, MRPL21, TOP1 FFAR3 3551/4885HDAC3 996/4885HDAC1 56/4885
US-20130065248-A1 REAGENTS AND METHODS FOR SIRTUIN CAPTURE SIRT3, SIRT1, SIRT2 FFAR3 4195/4885HDAC3 11/4885HDAC1 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.